HUP0203972A2 - Antigént és glikolipidet tartalmazó készítmény szublingvális úton történő alkalmazásra - Google Patents

Antigént és glikolipidet tartalmazó készítmény szublingvális úton történő alkalmazásra

Info

Publication number
HUP0203972A2
HUP0203972A2 HU0203972A HUP0203972A HUP0203972A2 HU P0203972 A2 HUP0203972 A2 HU P0203972A2 HU 0203972 A HU0203972 A HU 0203972A HU P0203972 A HUP0203972 A HU P0203972A HU P0203972 A2 HUP0203972 A2 HU P0203972A2
Authority
HU
Hungary
Prior art keywords
antigen
composition
production
glycolipid adjuvant
sublingual administration
Prior art date
Application number
HU0203972A
Other languages
English (en)
Inventor
Christopher Wallace Cluff
Garry Elliott
Alan Wheeler
Original Assignee
Allergy Therapeutics Limited
Corixa Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9883730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0203972(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergy Therapeutics Limited, Corixa Corporation filed Critical Allergy Therapeutics Limited
Publication of HUP0203972A2 publication Critical patent/HUP0203972A2/hu
Publication of HUP0203972A3 publication Critical patent/HUP0203972A3/hu
Publication of HU230545B1 publication Critical patent/HU230545B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány tárgyát legalább egy antigént és glikolipid-adjuvánsttartalmazó készítmény szublingvális úton történő alkalmazása képezimukozális és szisztémás immunitás kiváltására. A találmány tárgyátképezik továbbá a találmány szerint alkalmazott készítmények,eljárások a találmány szerinti készítmények előállítására, valamint akészítmények alkalmazása fertőzések, autoimmunitás, tumor vagyallergia kezelésére, megelőzésére vagy a felsoroltakkal szembenifogékonyság csökkentésére alkalmas gyógyszerek és az antigéntfelismerő ellenanyagok előállítására. A találmány szerinti megoldásprofilaktikus vagy terápiás vakcinaként alkalmas immunizálásra,allergia kezelésére, vagy ellenanyagok termeltetésére. Ó
HU0203972A 2000-01-14 2001-01-15 Antigént és glikolipidet tartalmazó készítmény szublingvális úton történő alkalmazásra HU230545B1 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0000891.2 2000-01-14
GBGB0000891.2A GB0000891D0 (en) 2000-01-14 2000-01-14 Formulation
PCT/GB2001/000142 WO2001051082A1 (en) 2000-01-14 2001-01-15 Composition of antigen and glycolipid adjuvant sublingual administration

Publications (3)

Publication Number Publication Date
HUP0203972A2 true HUP0203972A2 (hu) 2003-03-28
HUP0203972A3 HUP0203972A3 (en) 2011-02-28
HU230545B1 HU230545B1 (hu) 2016-11-28

Family

ID=9883730

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203972A HU230545B1 (hu) 2000-01-14 2001-01-15 Antigént és glikolipidet tartalmazó készítmény szublingvális úton történő alkalmazásra

Country Status (15)

Country Link
US (1) US8470331B2 (hu)
EP (3) EP2322212A1 (hu)
JP (1) JP4648603B2 (hu)
AR (1) AR027924A1 (hu)
AU (1) AU2001228625A1 (hu)
CA (1) CA2397359C (hu)
CZ (1) CZ304941B6 (hu)
DE (1) DE60139305D1 (hu)
DK (1) DK2100616T3 (hu)
ES (2) ES2561360T3 (hu)
GB (2) GB0000891D0 (hu)
HU (1) HU230545B1 (hu)
PL (1) PL356963A1 (hu)
SK (1) SK288411B6 (hu)
WO (1) WO2001051082A1 (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060052757A1 (en) * 1996-06-04 2006-03-09 Vance Products Incorporated, D/B/A Cook Urological Incorporated Implantable medical device with analgesic or anesthetic
US20060030826A1 (en) * 1996-06-04 2006-02-09 Vance Products Incorporated,d/b/a Cook Urological Incorporated Implantable medical device with anti-neoplastic drug
US20060025726A1 (en) * 1996-06-04 2006-02-02 Vance Products Incorporated, D/B/A Cook Urological Incorporated Implantable medical device with pharmacologically active layer
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
WO2004047793A1 (en) 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
WO2005115449A1 (en) * 2004-05-28 2005-12-08 Alk-Abelló A/S Method of treating allergy and infection by eliciting an iga antibody response
ITMI20061117A1 (it) * 2006-06-09 2007-12-10 Michele Bonanomi Una composizione farmaceutica per la somministrazione sublinguale di vaccini metodo per la sua preparazione e sui usi
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
CN101516396B (zh) 2006-09-26 2013-10-09 传染性疾病研究院 包含合成佐剂的疫苗组合物
WO2010127144A1 (en) 2009-04-29 2010-11-04 Muniyappa Pravin K Device and method for the diagnosis of gastrointestinal allergy
US8722064B2 (en) 2009-06-05 2014-05-13 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
GB201009273D0 (en) * 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
EP3632463A1 (en) 2011-04-08 2020-04-08 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
JP5650780B2 (ja) 2012-04-04 2015-01-07 日東電工株式会社 ワクチン組成物
NZ701881A (en) 2012-05-16 2016-10-28 Immune Design Corp Vaccines for hsv-2
EP3711768A1 (en) 2013-04-18 2020-09-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
WO2017173398A1 (en) 2016-04-01 2017-10-05 Duke University Alpha-helical peptide nanofibers as a self-adjuvanting vaccine platform
JP2023518924A (ja) * 2020-03-24 2023-05-09 チョル アン，ビョン 幼い哺乳動物の粘膜関連伝染性疾病を予防または治療するための血清組成物の製造方法、前記方法によって製造された血清組成物及びその用途
KR102151962B1 (ko) 2020-03-24 2020-09-04 안병철 어린 포유동물의 전염성 질병을 예방 또는 치료하기 위한 혈청 조성물의 제조방법, 상기 방법에 의해 제조된 혈청 조성물 및 이의 용도

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1128637A (en) 1966-09-13 1968-09-25 Beecham Group Ltd Influenza vaccine
US3541201A (en) 1968-12-18 1970-11-17 Ethan Alan Brown Novel sodium chloride encapsulated injectionable substances
GB1377074A (en) 1971-07-13 1974-12-11 Beecham Group Ltd Process for preparing injectable compositions
GB1492973A (en) 1974-02-16 1977-11-23 Beecham Group Ltd Process for preparing injectable compositions
US4070455A (en) * 1974-02-16 1978-01-24 Beecham Group Limited Process for preparing injectable desensitizing compositions and products thereof in microparticle form
EP0182442B2 (en) 1978-12-22 1996-04-03 Biogen, Inc. Recombinant DNA molecules and their method of production
US4258029A (en) * 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4987237A (en) * 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
DE3521994A1 (de) * 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5244663A (en) * 1987-01-28 1993-09-14 Medibrevex Therapeutic method against allergy
US4975420A (en) * 1987-09-30 1990-12-04 University Of Saskatchewan Agents and procedures for provoking an immune response to GnRH and immuno sterilizing mammals
FR2621916B1 (fr) * 1987-10-19 1990-03-09 Bioeurope Derives de la l-tyrosine solubles dans l'eau et procede pour leur preparation
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB9106048D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccines
EP0640347A1 (en) 1992-03-03 1995-03-01 Daiichi Pharmaceutical Co., Ltd. Oral vaccine
PT761231E (pt) * 1992-06-25 2000-06-30 Smithkline Beecham Biolog Composicao de vacina contendo adjuvantes
JPH08508247A (ja) * 1993-03-11 1996-09-03 セクレテック，インク． 粘膜表面への免疫原の輸送における重合的粘膜付着体
EP1175912A1 (en) * 1993-03-23 2002-01-30 SmithKline Beecham Biologics SA Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
AU676340B2 (en) 1993-05-25 1997-03-06 Wyeth Holdings Corporation Adjuvants for vaccines against respiratory syncytial virus
CA2167691A1 (en) * 1993-08-27 1995-03-02 Martin J. Blaser Campylobacter jejuni antigens, and methods for their production and use
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5514665A (en) 1993-12-30 1996-05-07 University Of British Columbia Method of preventing or reducing the risk of infection by bacterial pathogens utilizing simple and conjugated dextrans
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5646115A (en) * 1994-10-07 1997-07-08 Heska Corporation Ectoparasite saliva proteins and apparatus to collect such proteins
AU4977896A (en) * 1995-02-17 1996-09-04 Immunotherapy, Inc. Immunotherapy screening, prognosis, and treatment methods and compositions
KR100201352B1 (ko) * 1995-03-16 1999-06-15 성재갑 단일주사 백신 제형
GB9508785D0 (en) 1995-04-29 1995-06-21 Smithkline Beecham Plc Novel compositions
US5762943A (en) * 1996-05-14 1998-06-09 Ribi Immunochem Research, Inc. Methods of treating type I hypersensitivity using monophosphoryl lipid A
US5973128A (en) * 1996-11-22 1999-10-26 The Hospital For Sick Children Research And Development Lp Glycolipid mimics and methods of use thereof
WO1998040097A2 (en) * 1997-03-10 1998-09-17 Bayer Corporation Bovine respiratory and enteric coronavirus as a vaccine
US6491919B2 (en) * 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
NZ338101A (en) * 1997-04-01 2002-03-28 Corixa Corp Adjuvant compositions of Monophosphoryl Lipid A (MPL) and a phospholipid based surfactant (1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC)) suitable for intranasal administration
GB9706957D0 (en) * 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
AU7983198A (en) * 1997-06-23 1999-01-04 Ludwig Institute For Cancer Research Improved methods for inducing an immune response
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
WO1999024577A1 (en) 1997-11-10 1999-05-20 Statens Serum Institut NUCLEIC ACID FRAGMENTS AND POLYPEPTIDE FRAGMENTS DERIVED FROM $i(M. TUBERCULOSIS)
AU4563099A (en) * 1998-06-11 1999-12-30 Trustees Of The University Of Pennsylvania, The Methods and compositions for delivering proteins to macrophage cells and cells of macrophage derived lineage
WO1999066043A1 (en) 1998-06-12 1999-12-23 Smithkline Beecham Biologicals S.A. Recombinant production of toxoplasma sag1 antigen
EP1087788A1 (fr) 1998-06-26 2001-04-04 Aventis Pasteur Immunisation a ciblage mucosal
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6734172B2 (en) * 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
ES2173679T3 (es) * 1999-01-27 2002-10-16 Idea Ag Inmunizacion/transporte transnasal con vehiculos altamente adaptables.
EP2275133A1 (en) * 1999-02-26 2011-01-19 Novartis Vaccines and Diagnostics, Inc. Use of bioadhesives and adjuvants for the mucosal delivery of antigens
GB9909077D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
EP1173573A1 (en) * 1999-04-23 2002-01-23 Pharmexa A/S Method for down-regulating il5 activity
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
WO2000076476A1 (en) 1999-06-11 2000-12-21 Endorex Corporation Adjuvant-containing polymerized liposomes for oral, mucosal or intranasal vaccination
GB9924529D0 (en) * 1999-10-15 1999-12-15 Smithkline Beecham Biolog Novel compounds
AU2001264079A1 (en) 2000-06-14 2001-12-24 William Leslie Porter Lipids for modulating immune response
GB0020089D0 (en) 2000-08-15 2000-10-04 Smithkline Beecham Biolog Vaccine Composition

Also Published As

Publication number Publication date
GB0101035D0 (en) 2001-02-28
GB2360210A (en) 2001-09-19
JP2003519669A (ja) 2003-06-24
ES2328336T5 (es) 2016-06-21
EP2100616B1 (en) 2015-11-25
GB2360210B (en) 2004-12-15
PL356963A1 (en) 2004-07-12
DK2100616T3 (en) 2016-02-08
WO2001051082A1 (en) 2001-07-19
EP1255563A1 (en) 2002-11-13
EP1255563B2 (en) 2016-03-02
CZ20022417A3 (cs) 2003-03-12
US8470331B2 (en) 2013-06-25
CZ304941B6 (cs) 2015-02-04
JP4648603B2 (ja) 2011-03-09
CA2397359A1 (en) 2001-07-19
AR027924A1 (es) 2003-04-16
CA2397359C (en) 2012-06-05
EP1255563B1 (en) 2009-07-22
EP2322212A1 (en) 2011-05-18
AU2001228625A1 (en) 2001-07-24
DE60139305D1 (de) 2009-09-03
ES2561360T3 (es) 2016-02-25
US20030165512A1 (en) 2003-09-04
GB0000891D0 (en) 2000-03-08
HU230545B1 (hu) 2016-11-28
EP2100616A2 (en) 2009-09-16
EP2100616A3 (en) 2009-09-23
ES2328336T3 (es) 2009-11-12
SK10412002A3 (sk) 2003-05-02
SK288411B6 (sk) 2016-10-03
HUP0203972A3 (en) 2011-02-28

Similar Documents

Publication Publication Date Title
HUP0203972A2 (hu) Antigént és glikolipidet tartalmazó készítmény szublingvális úton történő alkalmazásra
HUP0402067A2 (hu) Oltóanyagok
HUP0301180A2 (hu) Imidazokinolinaminok adjuvánsként való használata DNS vakcinálásban
HUP0303720A2 (hu) Egy immunstimuláns oligonukleotidot és egy tokolt tartalmazó adjuvánskészítmény
NO20022531L (no) Vaksine for forebyggelse og behandling av Alzheimer- og amyloidrelaterte sykdommer
HUP0303996A2 (hu) Vakcinakészítmények
HUP0202885A2 (hu) Oltóanyagok
HUP9900061A1 (hu) Alumínium-foszfátra adszorbeált konjugált poliszacharid antigént tartalmazó vakcinakompozíciók
NO20015073D0 (no) Vaksiner
HUP0303173A2 (hu) Csökkent immunogenitású, módosított anti-EGFR-ellenanyagok
HUP0302965A2 (hu) Vakcina
AU2002302255A1 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
AP2002002592A0 (en) Vaccine for the prophylactic or therapeutic immunization against HIV.
DK1326636T3 (da) Vaccinesammensætning
HUP0102304A1 (hu) B Csoportba tartozó Streptococcus antigének
HUP9901109A2 (hu) Immunogén peptidek vakcinálásra és allergia kezelésére
WO2001058485A3 (en) Prophylactic and therapeutic antibodies against vaccina virus antigens
HUP0303372A2 (hu) Vakcina
MY125000A (en) Novel compositions
EP1471936A4 (en) HIV VACCINE AND METHOD OF USE
WO2001081380A3 (en) Immunogenic pneumococcal protein and vaccine compositions thereof
HUP0303431A2 (hu) PRRS vírus élő legyengített törzsei
HUP0104297A2 (hu) Szexuális úton terjedő betegségek elleni vakcina
WO2001070265A3 (en) Lipopeptide adjuvants
HUP0200162A2 (hu) Haemophilus somnus transzferrin-kötő fehérjék klónozása és expresszálása